Industry News
Pharmaceutical Industry News
China’s National Medical…
China’s National Medical Products Administration suspended the import, sale and use of Sun's rivastigmine hydrogen tartrate capsules after a virtual site inspection uncovered manufacturing shortfalls.
Nearly two decades after the…
Nearly two decades after the parties first floated the idea of a free trade agreement, the turbulence of the global market has prompted the European Union and India to carry their deal across the finish
After posting 16.2% revenue growth…
After posting 16.2% revenue growth in the last financial year, Servier President Olivier Laureau said the company has moved “one important step closer” to achieving an ambitious goal for 2030.
Pfizer again heads up a physician…
Pfizer again heads up a physician ranking of vaccine manufacturers, beating Merck & Co. and Moderna to complete an unchanged top three from the last edition of the survey. But while the rankings held steady,
Siegfried has signed agreements to…
Siegfried has signed agreements to acquire the controlled drug substance businesses of the Noramco Group and Extractas Bioscience. With the deals, Siegfried gains API sites in Wilmington, Delaware; Athens, Georgia; and Australia.
Following in the footsteps of…
Following in the footsteps of Phathom Pharmaceuticals' and Allergan Aesthetics’ own partnerships with “Saturday Night Live” stars, Teva Pharmaceuticals is turning to a famous funnyman to tackle a not-so-funny topic.
Catalent made a series of deals…
Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it's planning to wind down cell therapy manufacturing operations in the town.
The companies had committed to a…
The companies had committed to a five-year partnership in July 2024, in which Kowa agreed to promote the topical treatment to primary care physicians to extend the med's reach beyond dermatologists.
With Enhertu and Datroway, Daiichi…
With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. But the road to market leadership is growing more complex as the two AstraZeneca-partnered brands move into earlier lines of
Juggling a mix of customer demand…
Juggling a mix of customer demand and new regulations, Recipharm has built out a new facility in Bengaluru, India, to produce nonbacterial beta-lactam tablets. By commissioning the plant, Recipharm says it has lassoed up a
GLP-1 giant Eli Lilly has once…
GLP-1 giant Eli Lilly has once again taken to the medium of short film to get an important message about obesity across.
The new chairman of the CDC’s…
The new chairman of the CDC's Advisory Committee on Immunization Practices, Kirk Milhoan, M.D., Ph.D., recently took to the podcast “Why Should I Trust You” to answer exactly that.
ST Pharm has struck a $56 million…
ST Pharm has struck a $56 million deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for a new oligonucleotide treatment. The Korean CDMO revealed the contract Friday in a regulatory filing.
A potential inflection point that…
A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a setback that leaves a $2
In the second week of oral…
In the second week of oral Wegovy’s launch, which ended Jan. 16, the obesity pill logged roughly 18,400 total prescriptions, according to IMS data cited by Jefferies. That performance is a fair bit better than
¿Tu botiquín es un desastre?
Tener los medicamentos básicos adecuados puede facilitar el tratamiento de algunos malestares en casa.
Plotting a challenge to…
Plotting a challenge to Regeneron’s blockbuster Eylea, Ocular Therapeutix has hired “a key architect” of its rival’s launch to head its commercial team.
Big Insurers Try to Shift Blame for High Health Costs to Hospitals and Drug Makers
At two congressional hearings, lawmakers slammed executives of major companies, saying they were failing to rein in the cost of medical care for consumers.
Astellas CEO said he doesn’t want…
Astellas CEO said he doesn't want to make acquisitions simply to fill a revenue gap. Takeda is preparing for Trintellix's U.S. patent expiry with a round of layoffs. Chugai's CEO is seeking name recognition as
While the threat of U.S. import…
While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026, according to a new report from financial services firm